利妥昔单抗在特发性膜性肾病中的治疗

Zou Peimei; Li Hang; Cai Jianfang; Chen Zhenjie; Li Chao; Li Xuewang

doi:10.24920/21803

Your Location：

Home >

Browse articles >

利妥昔单抗在特发性膜性肾病中的治疗

Chinese Medicine Science Journal Vol. 33, Issue 1, Pages: 9-19(2018)

ORIGINAL ARTICLE | Updated：2024-04-10

- 利妥昔单抗在特发性膜性肾病中的治疗
- Affiliations：
  
  Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China
- Author bio：
- Funds：
- DOI：10.24920/21803
  CLC：
- Received：31 July 2017，
  
  Published Online：13 February 2018，
  
  Published：01 April 2018
- Accepted：
Scan QR Code
Zou Peimei, Li Hang, Cai Jianfang, et al. 利妥昔单抗在特发性膜性肾病中的治疗[J]. Chinese medicine science journal, 2018, 33(1): 9-19.
DOI：

Zou Peimei, Li Hang, Cai Jianfang, et al. 利妥昔单抗在特发性膜性肾病中的治疗[J]. Chinese medicine science journal, 2018, 33(1): 9-19. DOI： 10.24920/21803.

摘要

Abstract

关键词

Keywords

references

Schieppati A , Mosconi L , Perna A , et al . Prognosis of untreated patients with idiopathic membranous nephropathy . N Engl J Med , 1993 ; 329 ( 2 ): 85 - 9 . doi: 10.1056/NEJM199307083290203 https://doi.org/10.1056/NEJM199307083290203 . DOI: 10.1007/BF00866338 http://doi.org/10.1007/BF00866338 http://www.nejm.org/doi/abs/10.1056/NEJM199307083290203 http://www.nejm.org/doi/abs/10.1056/NEJM199307083290203

Chen Y , Schieppati A , Chen X , et al . Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome . Cochrane Database Syst Rev 2014 ; (10):CD004293. doi: 10.1002/14651858.CD004293.pub3 https://doi.org/10.1002/14651858.CD004293.pub3 .

Beck LH , Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy . N Engl J Med , 2009 ; 361 ( 1 ): 11 - 21 . doi: 10.1056/NEJMoa0810457 https://doi.org/10.1056/NEJMoa0810457 . DOI: 10.1056/NEJMoa0810457 http://doi.org/10.1056/NEJMoa0810457 http://www.nejm.org/doi/abs/10.1056/NEJMoa0810457 http://www.nejm.org/doi/abs/10.1056/NEJMoa0810457

Cattran D . Management of membranous nephropathy: when and what for treatment . J Am Soc Nephrol , 2005 ; 16 ( 5 ): 1188 - 94 . doi: 10.1681/ASN.2005010028 https://doi.org/10.1681/ASN.2005010028 . DOI: 10.1681/ASN.2005010028 http://doi.org/10.1681/ASN.2005010028 http://www.jasn.org/cgi/doi/10.1681/ASN.2005010028 http://www.jasn.org/cgi/doi/10.1681/ASN.2005010028

Cattran DC . Idiopathic membranous glomerulonephritis . Kidney Int , 2001 ; 59 ( 5 ): 1983 - 94 . doi: 10.1046/j.1523-1755.2001.0590051983.x https://doi.org/10.1046/j.1523-1755.2001.0590051983.x . DOI: 10.1046/j.1523-1755.2001.0590051983.x http://doi.org/10.1046/j.1523-1755.2001.0590051983.x http://linkinghub.elsevier.com/retrieve/pii/S0085253815476926 http://linkinghub.elsevier.com/retrieve/pii/S0085253815476926

Sinha A , Bagga A . Rituximab therapy in nephrotic syndrome: implications for patients’ management . Nat Rev Nephrol , 2013 ; 9 ( 3 ): 154 - 69 . doi: 10.1038/nrneph.2012.289 https://doi.org/10.1038/nrneph.2012.289 . DOI: 10.1038/nrneph.2012.289 http://doi.org/10.1038/nrneph.2012.289 http://www.nature.com/nrneph/journal/v9/n3/abs/nrneph.2012.289.html http://www.nature.com/nrneph/journal/v9/n3/abs/nrneph.2012.289.html

Remuzzi G , Chiurchiu C , Abbate M , et al . Rituximab for idiopathic membranous nephropathy . Lancet , 2002 ; 360 ( 9337 ): 923 - 4 . doi: 10.1016/S0140-6736(02)11042-7 https://doi.org/10.1016/S0140-6736(02)11042-7 . DOI: 10.1016/S0140-6736(02)11042-7 http://doi.org/10.1016/S0140-6736(02)11042-7 http://linkinghub.elsevier.com/retrieve/pii/S0140673602110427 http://linkinghub.elsevier.com/retrieve/pii/S0140673602110427

Moher D , Liberati A , Tetzlaff J , et al . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement . Int J Surg , 2010 ; 8 ( 5 ): 336 - 41 . doi: 10.1016/j.ijsu.2010.02.007 https://doi.org/10.1016/j.ijsu.2010.02.007 . DOI: 10.1016/j.ijsu.2010.02.007 http://doi.org/10.1016/j.ijsu.2010.02.007 http://linkinghub.elsevier.com/retrieve/pii/S1743919110000403 http://linkinghub.elsevier.com/retrieve/pii/S1743919110000403

Fervenza FC , Canetta PA , Barbour SJ , et al . A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (MENTOR) . Nephron , 2015 ; 130 ( 3 ): 159 - 68 . doi: 10.1159/000430849 https://doi.org/10.1159/000430849 . DOI: 10.1159/000430849 http://doi.org/10.1159/000430849 https://www.karger.com/Article/FullText/430849 https://www.karger.com/Article/FullText/430849

Rojas-Rivera J , Fernandez-Juarez G , Ortiz A , et al . A European multicentre and open-label controlled randomized trial to evaluate the efficacy of sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study . Clin Kidney J , 2015 ; 8 ( 5 ): 503 - 10 . doi: 10.1093/ckj/sfv075 https://doi.org/10.1093/ckj/sfv075 . DOI: 10.1093/ckj/sfv075 http://doi.org/10.1093/ckj/sfv075 https://academic.oup.com/ckj/article-lookup/doi/10.1093/ckj/sfv075 https://academic.oup.com/ckj/article-lookup/doi/10.1093/ckj/sfv075

Beck LH Jr ., Fervenza FC , Beck DM , et al . Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy . J Am Soc Nephrol , 2011 ; 22 ( 8 ): 1543 - 50 . doi: 10.1681/ASN.2010111125 https://doi.org/10.1681/ASN.2010111125 . DOI: 10.1681/ASN.2010111125 http://doi.org/10.1681/ASN.2010111125 http://www.jasn.org/cgi/doi/10.1681/ASN.2010111125 http://www.jasn.org/cgi/doi/10.1681/ASN.2010111125

Irazabal MV , Eirin A , Lieske J , et al . Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study . Nephrol Dial Transplant , 2013 ; 28 ( 1 ): 137 - 46 . doi: 10.1093/ndt/gfs379 https://doi.org/10.1093/ndt/gfs379 . DOI: 10.1093/ndt/gfs379 http://doi.org/10.1093/ndt/gfs379 https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs379 https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs379

Segarra A , Praga M , Ramos N , et al . Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients . Clin J Am Soc Nephrol , 2009 ; 4 ( 6 ): 1083 - 8 . doi: 10.2215/CJN.06041108 https://doi.org/10.2215/CJN.06041108 . DOI: 10.2215/CJN.06041108 http://doi.org/10.2215/CJN.06041108 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.06041108 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.06041108

Dahan K , Debiec H , Plaisier E , et al . Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up . J Am Soc Nephrol , 2017 ; 28 ( 1 ): 348 - 58 . doi: 10.1681/ASN.2016040449 https://doi.org/10.1681/ASN.2016040449 . DOI: 10.1681/ASN.2016040449 http://doi.org/10.1681/ASN.2016040449 http://www.jasn.org/lookup/doi/10.1681/ASN.2016040449 http://www.jasn.org/lookup/doi/10.1681/ASN.2016040449

Cravedi P , Ruggenenti P , Sghirlanzoni MC , et al . Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy . Clin J Am Soc Nephrol , 2007 ; 2 ( 5 ): 932 - 7 . doi: 10.2215/CJN.01180307 https://doi.org/10.2215/CJN.01180307 . DOI: 10.2215/CJN.01180307 http://doi.org/10.2215/CJN.01180307 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01180307 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01180307

Cravedi P , Sghirlanzoni MC , Marasa M , et al . Efficacy and safety of rituximab second-line therapy for membranous nephropathy: a prospective, matched-cohort study . Am J Nephrol , 2011 ; 33 ( 5 ): 461 - 8 . doi: 10.1159/000327611 https://doi.org/10.1159/000327611 . DOI: 10.1159/000327611 http://doi.org/10.1159/000327611 https://www.karger.com/Article/FullText/327611 https://www.karger.com/Article/FullText/327611

Fervenza FC , Abraham RS , Erickson SB , et al . Rituximab therapy in idiopathic membranous nephropathy: a 2-year study . Clin J Am Soc Nephrol , 2010 ; 5 ( 12 ): 2188 - 98 . doi: 10.2215/CJN.05080610 https://doi.org/10.2215/CJN.05080610 . DOI: 10.2215/CJN.05080610 http://doi.org/10.2215/CJN.05080610 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.05080610 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.05080610

Fervenza FC , Cosio FG , Erickson SB , et al . Rituximab treatment of idiopathic membranous nephropathy . Kidney Int , 2008 ; 73 ( 1 ): 117 - 25 . doi: 10.1038/sj.ki.5002628 https://doi.org/10.1038/sj.ki.5002628 . DOI: 10.1038/sj.ki.5002628 http://doi.org/10.1038/sj.ki.5002628 http://linkinghub.elsevier.com/retrieve/pii/S0085253815528305 http://linkinghub.elsevier.com/retrieve/pii/S0085253815528305

Moroni G , Depetri F , Del Vecchio L , et al . Low-dose rituximab is poorly effective in patients with primary membranous nephropathy . Nephrol Dial Transplant , 2017 ; 32 ( 10 ): 1691 - 6 . doi: 10.1093/ndt/gfw251 https://doi.org/10.1093/ndt/gfw251 . DOI: 10.1093/ndt/gfw251 http://doi.org/10.1093/ndt/gfw251 http://europepmc.org/abstract/MED/27387472 http://europepmc.org/abstract/MED/27387472

Ruggenenti P . Rituximab in idiopathic membranous nephropathy: a one-year prospective study . J Am Soci Nephrol , 2003 ; 14 ( 7 ): 1851 - 7 . doi: 10.1097/01.ASN.0000071511.35221.B3 https://doi.org/10.1097/01.ASN.0000071511.35221.B3 . DOI: 10.1097/01.ASN.0000071511.35221.B3 http://doi.org/10.1097/01.ASN.0000071511.35221.B3 http://www.jasn.org/cgi/doi/10.1097/01.ASN.0000071511.35221.B3 http://www.jasn.org/cgi/doi/10.1097/01.ASN.0000071511.35221.B3

Ruggenenti P , Chiurchiu C , Abbate M , et al . Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol , 2006 ; 1 ( 4 ): 738 - 48 . doi: 10.2215/CJN.01080905 https://doi.org/10.2215/CJN.01080905 . DOI: 10.2215/CJN.01080905 http://doi.org/10.2215/CJN.01080905 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01080905 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.01080905

Troyanov S , Wall CA , Miller JA , et al . Idiopathic membranous nephropathy: definition and relevance of a partial remission . Kidney Int , 2004 ; 66 ( 3 ): 1199 - 205 . doi: 10.1111/j.1523-1755.2004.00873.x https://doi.org/10.1111/j.1523-1755.2004.00873.x . DOI: 10.1111/j.1523-1755.2004.00873.x http://doi.org/10.1111/j.1523-1755.2004.00873.x http://linkinghub.elsevier.com/retrieve/pii/S0085253815501749 http://linkinghub.elsevier.com/retrieve/pii/S0085253815501749

Polanco N , Gutierrez E , Covarsi A , et al . Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy . J Am Soc Nephrol , 2010 ; 21 ( 4 ): 697 - 704 . doi: 10.1681/ASN.2009080861 https://doi.org/10.1681/ASN.2009080861 . DOI: 10.1681/ASN.2009080861 http://doi.org/10.1681/ASN.2009080861 http://www.jasn.org/cgi/doi/10.1681/ASN.2009080861 http://www.jasn.org/cgi/doi/10.1681/ASN.2009080861

Looney RJ , Anolik JH , Campbell D , et al . B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab . Arthritis Rheum , 2004 ; 50 ( 8 ): 2580 - 9 . doi: 10.1002/art.20430 https://doi.org/10.1002/art.20430 . DOI: 10.1002/(ISSN)1529-0131 http://doi.org/10.1002/(ISSN)1529-0131 http://doi.wiley.com/10.1002/%28ISSN%291529-0131 http://doi.wiley.com/10.1002/%28ISSN%291529-0131

Zucchelli P , Ponticelli C , Cagnoli L , et al . Prognostic value of T lymphocyte subset ratio in idiopathic membranous nephropathy . Am J Nephrol , 1988 ; 8 ( 1 ): 15 - 20 . DOI: 10.1159/000167547 http://doi.org/10.1159/000167547 https://www.karger.com/Article/FullText/167547 https://www.karger.com/Article/FullText/167547

Ruggenenti P , Debiec H , Ruggiero B , et al . Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy . J Am Soc Nephrol , 2015 ; 26 ( 10 ): 2545 - 58 . doi: 10.1681/ASN.2014070640 https://doi.org/10.1681/ASN.2014070640 . DOI: 10.1681/ASN.2014070640 http://doi.org/10.1681/ASN.2014070640 http://www.jasn.org/cgi/doi/10.1681/ASN.2014070640 http://www.jasn.org/cgi/doi/10.1681/ASN.2014070640

Ordoñez JD , Hiatt RA , Killebrew EJ , et al . The increased risk of coronary heart disease associated with nephrotic syndrome . Kidney International , 1993 ; 44 ( 3 ): 638 - 42 . DOI: 10.1038/ki.1993.292 http://doi.org/10.1038/ki.1993.292 http://linkinghub.elsevier.com/retrieve/pii/S0085253815581738 http://linkinghub.elsevier.com/retrieve/pii/S0085253815581738

Lee T , Derebail VK , Kshirsagar AV , et al . Patients with primary membranous nephropathy are at high risk of cardiovascular events . Kidney Int , 2016 ; 89 ( 5 ): 1111 - 8 . doi: 10.1016/j.kint.2015.12.041 https://doi.org/10.1016/j.kint.2015.12.041 . DOI: 10.1016/j.kint.2015.12.041 http://doi.org/10.1016/j.kint.2015.12.041 http://linkinghub.elsevier.com/retrieve/pii/S0085253816002751 http://linkinghub.elsevier.com/retrieve/pii/S0085253816002751

Lefaucheur C , Stengel B , Nochy D , et al . Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association . Kidney Int , 2006 ; 70 ( 8 ): 1510 - 7 . doi: 10.1038/sj.ki.5001790 https://doi.org/10.1038/sj.ki.5001790 . DOI: 10.1038/sj.ki.5001790 http://doi.org/10.1038/sj.ki.5001790 http://linkinghub.elsevier.com/retrieve/pii/S0085253815521674 http://linkinghub.elsevier.com/retrieve/pii/S0085253815521674

Ponticelli C , Glassock RJ . Glomerular diseases: membranous nephropathy—a modern view . Clin J Am Soc Nephrol , 2014 ; 9 ( 3 ): 609 - 16 . doi: 10.2215/CJN.04160413 https://doi.org/10.2215/CJN.04160413 . DOI: 10.2215/CJN.04160413 http://doi.org/10.2215/CJN.04160413 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.04160413 http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.04160413

Views

2514

Downloads

CSCD

Alert me when the article has been cited

Submit

Publicity Resources

Association between GSTT1 Homozygous Deletion and Risk of Pancreatic Cancer: A Meta Analysis

Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials

Related Author

Cui Junpeng

Lin Meiyi

Liu Zhenghao

Liu Baolin

Yang Yingying

Pan Hui

Wang Bo

Chen Shi

Related Institution

Sixth Department of General Surgery, Shengjing Hospital of China Medical University

Department of Rheumatology, First Affiliated Hospital of China Medical University

China Medical University

Department of Endocrinology, Key Laboratory of Endocrinology of Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College

Health Science Popularization Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College

⁰